Barry J. Materson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barry J. Materson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Fornoni
Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida
3 shared publications Manuel Garcia-Estrada
Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
2 shared publicationsOliver Lenz
2 shared publicationsRichard A. Preston
Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA; Jackson Memorial Medical Center, Miami, FL, USA; Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
2 shared publications- Richard A. Preston
Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA
2 shared publications Thor Tejada
Division of Nephrology and Hypertension, Department of Medicine, Miller School of Medicine, University of Miami OPPRP (D-54), PO Box 016960, Miami, FL 33101, USA
2 shared publications
Latest Publications
- 1 November 2017
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 11 (11) , 704-708
Prehypertension is real and can be associated with target organ damage
- 1 November 2017
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 11 (11) , 704-708
Prehypertension is real and can be associated with target organ damage
- 1 June 2016
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 10 (6) , 536-541
Hypertension in the frail elderly
- 1 June 2016
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 10 (6) , 536-541
Hypertension in the frail elderly
- 11 April 2016
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 10 (6) , 474-475
Allopurinol: can it undo the harm done by high dietary fructose?
- 11 April 2016
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 10 (6) , 474-475
Allopurinol: can it undo the harm done by high dietary fructose?
- 1 July 2015
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 9 (7) , 504-506
Goal blood pressure for cognition–impaired patients: let's treat the patients—not the numbers
- 1 July 2015
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 9 (7) , 504-506
Goal blood pressure for cognition–impaired patients: let's treat the patients—not the numbers
- 1 July 2014
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 8 (7) , 514-6
Attempts to define the risk of elevated blood pressure.
- 1 July 2014
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 8 (7) , 514-6
Attempts to define the risk of elevated blood pressure.
- 12 March 2014
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 16 (4) , 249-250
JNC 8 at Last! No Holy Grail in Hand, but Useful Recommendations
- 12 March 2014
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 16 (4) , 249-250
JNC 8 at Last! No Holy Grail in Hand, but Useful Recommendations
- 29 July 2013
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 15 (10) , 704
JNC 8 Transmogrified
- 29 July 2013
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 15 (10) , 704
JNC 8 Transmogrified
- Open Access
- 28 October 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (11) , 646-647
Easily “Curable” Anxiety‐Induced Hypertension
- 28 October 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (11) , 646-647
Open AccessEasily “Curable” Anxiety‐Induced Hypertension
- 1 October 2007
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 9 (10) , 796-799
Enhancing Dosage Flexibility in Combination Therapy
- 1 October 2007
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 9 (10) , 796-799
Enhancing Dosage Flexibility in Combination Therapy
- 22 July 2007
- Published by Springer Nature in Current Hypertension Reports
- Vol. 9 (4) , 284-290
Combination therapy with renin-angiotensin system blockers: Will amlodipine replace hydrochlorothiazide?
Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker. It is even more effective when used in combination with other antihypertensive medications, including hydrochlorothiazide. When antihypertensive calcium channel blockers were first introduced, evidence in the laboratory that they had some natriuretic properties was adduced to suggest that they would be “the diuretics of the 1990s.” This turned out not to be the case. Because of its clinical efficacy, amlodipine is frequently used in fixed-dose combination products, but it is not likely to replace hydrochlorothiazide.
- 22 July 2007
- Published by Springer Nature in Current Hypertension Reports
- Vol. 9 (4) , 284-290
Combination therapy with renin-angiotensin system blockers: Will amlodipine replace hydrochlorothiazide?
Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker. It is even more effective when used in combination with other antihypertensive medications, including hydrochlorothiazide. When antihypertensive calcium channel blockers were first introduced, evidence in the laboratory that they had some natriuretic properties was adduced to suggest that they would be “the diuretics of the 1990s.” This turned out not to be the case. Because of its clinical efficacy, amlodipine is frequently used in fixed-dose combination products, but it is not likely to replace hydrochlorothiazide.